Genetic and epigenetic mechanisms for the development of endometrial hyperplasia in women of reproductive age
AbstractSuch diseases as obesity, thyroid diseases, urinary tract diseases, hypertension, pelvic inflammatory diseases, adenomyosis, benign mammary gland dysplasia, uterine fibroids, which are quite common in the population and represent a background for the occurrence, are associated with the risk of malignancy of endometrial hyperplasia diseases.
We were able to establish that genetic (ERS1, PRG), epigenetic (miR-210, miR-18a, miR-221, miR-222) changes that predict future pathogenesis of possible recurrence of endometrial hyperplasia and cancer are predictors of malignancy endometrium, organ-preserving treatment methods.
Keywords:epigenetics, microRNA, forecast, hyperplasia endometrium, cancer endometrium
Funding. The study had no sponsor support.
Conflict of interests. The authors declare no conflict of interests.
For citation: Ordiyants I.M., Kuular A.A., Yamurzina A.A., Huseynova R.G., Novginov D.S. Genetic and epigenetic mechanisms for the development of endometrial hyperplasia in women of reproductive age. Akusherstvo i ginekologiya: novosti, mneniya, obuchenie [Obstetrics and Gynecology: News, Opinions, Training]. 2020; 8 (3): 67-70. DOI: 10.24411/2303-9698-2020-13009 (in Russian)
References
1. Tabakman Yu.Yu, Solopova A.G., Bishtavi A.Kh. Idrisova L.E. Endometrial hyperplasia: controversial issues of pathogenesis and therapy. Akusherstvo, ginekologiya i reproduktsiya [Obstetrics, Gynecology and Reproduction]. 2016; 10 (3): 5-10. (in Russian)
2. Gallos I.D., Alazzam M., Clark T.J., Faraj R., Rosenthal A., Smith P.P., et al. Management of endometrial hyperplasia. Green-top Guideline No. 67. RCOG/BSGE Joint Guideline. 2016: 31.
3. Venediktova M.G., Dobrokhotova Yu.E. Oncogynecology in the practice of a gynecologist. Moscow: GEOTAR-Media, 2015: 288 p. (in Russian)
4. Vovk I.B., Gorban’ N.E., Borisyuk O.Yu. Endometrial hyperplasia (clinical lecture). Zdorov’e zhenshchiny [Woman’s Health]. 2016; (5): 10-8. (in Russian)
5. Owings R.A., Quick C.M. Endometrial intraepithelial neoplasia.Arch Pathol Lab Med. 2014; 138: 484-91.
6. Eseneeva F.M., Shalaev O.N., Orazmuradov A.A., Radzinskiy V.E., Kuular A.A., Kiselev V.I., et al. WNT-signaling pathway for uterine myoma. Mat’ i ditya v Kuzbasse [Mother and Child in Kuzbass]. 2017; 2 (69): 33-8. (in Russian)
7. Ordiyants I.M., Arakelov S.E., Pavlova E.A., Dmitrieva E.V., Kuular A.A. Genetic risk of developing a hyperplastic process in the endometrium and in the mammary glands associated with polymorphism of candidate genes. Mat’ i ditya v Kuzbasse [Mother and Child in Kuzbass]. 2014; 4 (59): 62-5. (in Russian)
8. Javed Z., Ullah M., Ashfaq H.A., Shah A.H., Shahzad M., Bilal M., et al. Role of microRNA in endometrial carcinoma. Adv Life Sci. 2016; 4 (1): 8-13.
9. Jayaraman M., Radhakrishnan R., Mathews C.A., Yan M., Husain S., Moxley K.M., et al. Identification of novel diagnostic and prognostic miRNA signatures in endometrial cancer. Genes Cancer. 2017; 8 (5-6): 566-76.
10. Wilczynski M., Danielska J., Dzieniecka M., Malinowski A. The role of miRNA in endometrial cancer in the context of miRNA 205. Ginekol Pol. 2015; 86: 856-61.
11. Yanokura M., Banno K., Iida M., Irie H., Umene K., Masuda K., et al. MicroRNAS in endometrial cancer: recent advances and potential clinical applications. EXCLI J. 2015; 14: 190-8.
12. Nyante S.J. Genetic variation in estrogen and progesterone pathway genes and breast cancer risk: an exploration of tumor subtype-specific effects. Cancer Causes Control. 2015; 26: 121-31.
13. Patel B. Role of nuclear progesterone receptor isoforms in uterine pathophysiology. Hum Reprod Update. 2015; 21 (2): 155-73.
14. Xing-Ling Qi. No association between the progesterone receptor gene polymorphism (+331G/a) and the risk of breast cancer: an updated meta-analysis. BMC Med Genet. 2017; 18: 123.
15. Bavelloni A., Ramazzotti G., Poli A., Piazzi M., Focaccia E., Blalock W., et al. MiRNA-210: a current overview. Anticancer Res. 2017; 37: 6511-21.
16. Widodo Djati M.S., Rifai M. Role of MicroRNAs in carcinogenesis that potential for biomarker of endometrial cancer. Ann Med Surg. 2016; 7: 9-13.
17. Abak A., Amini S., Sakhinia E., Abhari A. MicroRNA-221: biogenesis, function and signatures in human cancers. Eur Rev Med Pharmacol Sci. 2018; 22 (10): 3094117.
18. Liu B., Che Q., Qiu H., Bao W., Chen X., Lu W., et al. Elevated MiR-222-3p promotes proliferation and invasion of endometrial carcinoma via targeting ERa. PLoS One. 2014; 9 (1): e87563.
19. Ordiyants I.M., Dmitrieva E.V., Kuular A.A., Novginov D.S., Eseneeva F.M. The level of expression of estrogen and progesterone receptors in the endometrium of women taking tamoxifen in postmenopausal women. Ul’yanovskiy mediko-biologicheskiy zhurnal [Medical and Biological Journal of Ul’yanovsk]. 2018; (2): 47-53. (in Russian)